Ultima Genomics Overview
Ultima Genomics is focused on driving the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company’s new sequencing architecture lowers the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. Ultima’s new sequencing architecture is designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century.
Latest News
growth-positive
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced results from a joint research collaboration with Ultima Genomics. The collaboration combines Compugens AI/ML-powered predictive computational discovery platform, Unigen, with Ultimas UG 100 sequencing platform to gain insights into gene structure for immuno-oncology. The research, presented at the Advances in Genome Biology and Technology 2025 General Meeting, highlights the potential of using single-cell sequencing to study gene splicing and tumor biology. Compugen plans to further leverage Ultimas technology to develop proprietary single-cell atlases for discovering new immunotherapies. The collaboration is seen as a significant step forward in cancer research, offering new opportunities for drug target discovery and development.
PartnersProduct Stage
Ultima Genomics to Launch UG 100™ System and Present Data at AGBT
Quest Diagnostics and Ultima Collaborate to Scale Ultima's Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set
growth-positive
Ultima Genomics Adds Tenured Strategic and Technology Leadership In Preparation for Commercial Launch
Ultima Genomics, a developer of ultra-high throughput sequencing architecture, has announced the appointment of two new executives. Mirna Jarosz, formerly General Manager of Integrated DNA Technologys (IDT) NGS business, will join as Head of Product Strategy, focusing on customer success, strategy, and commercial focus. Shlomey Derhi, former head of R&D for a large group within the Israel Defense Forces, will join as Head of Architecture and Integration, focusing on accelerating technology development. The appointments come as Ultima prepares for the commercial launch of its first product, the UG100.
Management Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $604.22M |
| Last funding | $600M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 7 |
Team Members
2
Employees: 201-500
Web & Social Links
| Website | www.ultimagenomics.com/ |
| Careers | Careers page |
Locations
Rehovot, Israel
Newark, CA 94560, USA
Photos & Videos
No files yet
Ultima Genomics Business
Business models
B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsGenesArtificial IntelligenceMachine LearningTags (5)
machine-learningdiagnosticsgeneticsgenome-editingbiotechnologyUltima Genomics Financials
$604.22M
Total funding
—
Capital raised
$600M
Last funding
Seed
Funding stage
2
Total rounds
7
Investors
Ultima Genomics Lifecycle
Ultima Genomics News
10 articles
growth-positive
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing...
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced results from a joint research collaboration with Ultima Genomics. The collaboration combines Compugens AI/ML-powered predictive computational discovery platform, Unigen, with Ultimas UG 100 sequencing platform to gain insights into gene structure for immuno-oncology. The research, presented at the Advances in Genome Biology and Technology 2025 General Meeting, highlights the potential of using single-cell sequencing to study gene splicing and tumor biology. Compugen plans to further leverage Ultimas technology to develop proprietary single-cell atlases for discovering new immunotherapies. The collaboration is seen as a significant step forward in cancer research, offering new opportunities for drug target discovery and development.
PartnersProduct Stage
Ultima Genomics to Launch UG 100™ System and Present Data at AGBT
Quest Diagnostics and Ultima Collaborate to Scale Ultima's Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
Ultima Genomics to Present at ASHG and Provide Updated Reference Data Set
growth-positive
Ultima Genomics Adds Tenured Strategic and Technology Leadership In Preparation for Commercial Launch
Ultima Genomics, a developer of ultra-high throughput sequencing architecture, has announced the appointment of two new executives. Mirna Jarosz, formerly General Manager of Integrated DNA Technologys (IDT) NGS business, will join as Head of Product Strategy, focusing on customer success, strategy, and commercial focus. Shlomey Derhi, former head of R&D for a large group within the Israel Defense Forces, will join as Head of Architecture and Integration, focusing on accelerating technology development. The appointments come as Ultima prepares for the commercial launch of its first product, the UG100.
Management Changes
growth-positive
Ultima Genomics and Genome Insight Collaborate to Bring Affordable Whole Genome Sequencing to Cancer Patients
Ultima Genomics and Genome Insight have entered into a partnership to provide affordable whole genome sequencing solutions to cancer patients. Genome Insight will join the early access program for Ultimas high-throughput NGS instrument platform, the UG 100™, and develop an optimized version of its whole genome bioinformatics solution for Ultimas sequencing technology. The partnership aims to make whole genome sequencing an affordable reality for cancer patients, providing important information for physicians in formulating a treatment strategy for each patient.
PartnersExpand
growth-positive
Ultima Genomics Announces Collaboration with 10x Genomics to Enable Seamless Integration of Chromium Single Cell Applications on Ultima Sequencers
Ultima Genomics and 10x Genomics have announced a collaboration to integrate the use of 10x Genomics Single Cell Gene Expression solutions with Ultimas ultra-high throughput sequencing systems. The partnership aims to provide researchers with streamlined and cost-effective workflows for analyzing gene expression in single cells at a larger scale. The combination of Ultimas sequencing platform with 10x Genomics technologies will enable customers to analyze samples more cost-effectively and interrogate larger and more complex single cell libraries. The collaboration is expected to accelerate genomic discovery and advance human health. Ultima Genomics is focused on driving the scale of genomic information, while 10x Genomics is a life science technology company building products for analyzing biological systems.
Partners
growth-positive
Ultima Genomics Partners with New England Biolabs® to Expand Research Applications on Ultima Sequencers
Ultima Genomics has announced a collaboration with New England Biolabs (NEB) to develop optimized next generation sequencing workflows. The collaboration aims to enable the use of NEBs NEBNext reagents and library preparation kits on Ultima sequencing platforms. The partnership will support DNA, RNA, and methylation sequencing applications. Ultima Genomics aims to provide high-performance end-to-end workflows to its customers, leveraging NEBs success in delivering high-quality molecular biology reagents and library preparation products. The collaboration is expected to result in new insights and discoveries for mutual customers. Ultima Genomics is focused on scaling genomic information to drive advances in biology and human health, while NEB is the industry leader in the discovery and production of enzymes for molecular biology applications.
Partners
growth-positive
Ultima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated Computing
Ultima Genomics has announced a collaboration with NVIDIA to leverage AI-accelerated analysis in DNA sequencing and analysis. The collaboration includes the use of NVIDIA GPUs for deep learning and will soon include acceleration of variant calling. Ultima Genomics has developed a new sequencing architecture and is currently in an early access program for its high-throughput next-generation sequencing instrument. The collaboration with NVIDIA will enable highly accurate and accelerated analysis for customers. Ultima Genomics has also announced partnerships to develop germline variant calling pipelines. The collaboration with NVIDIA will lower the total cost of ownership for customers and enable large-scale data initiatives in genomics.
PartnersInvestment
growth-positive
Genome sequencing co Ultima Genomics raises $600m
Ultima Genomics, a US-Israeli genome sequencing company, has emerged from stealth mode and announced $600 million in financing. The company has developed a sequencing machine that offers faster and cheaper genome sequencing compared to its rival Illumina. Ultima Genomics claims that its technology allows genome sequencing for $100, compared to the $500-600 cost of Illumina. The company aims to achieve genome sequencing down to single cells, enabling early diagnosis of illnesses like cancer. The technology also facilitates genetic research by providing more data about the genome. Ultima Genomics has managed to keep its product development and financing information confidential until now. The companys investors include Marius Nacht, D1 Capital, Andreessen Horowitz, General Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.
Investment
Employee Info
| Employees (range) | 201-500 |
| Exact count | 306 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Ultima Genomics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Maor Perlov |
| Registrar ID | 515787091 |
| Creator | Maor Perlov |
| Creator email | maor.perlov@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-01-22T00:00:00.000Z |
| Created | 2022-10-19T00:00:00.000Z |